Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

P. Geborek · Annals of the Rheumatic Diseases · 2005 · 429 citations · Full text

Medicine, Immunology, Internal Medicine +14

Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs

Vivian P. Bykerk, Pooneh Akhavan, Glen Hazlewood et al. · The Journal of Rheumatology · 2011 · 339 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

Anja Strangfeld, Franka Hierse, Rolf Rau et al. · Arthritis Research & Therapy · 2010 · 262 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis

Soko Setoguchi, Daniel H. Solomon, Michael E. Weinblatt et al. · Arthritis & Rheumatism · 2006 · 241 citations

Medicine, Pharmacology, Pharmacotherapy +13

Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma

Corrado Tarella, Roberto Passera, Michele Magni et al. · Journal of Clinical Oncology · 2010 · 167 citations · Full text

Medicine, Hematology, Oncology +16